Stock comparison
ResMed
Thermo Fisher Scientific
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$30.31B
Sector
Healthcare
TMO
Thermo Fisher Scientific
Market cap
$166.32B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | TMO | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 52C | RMD |
| Benjamin Graham | 75B | 72B | RMD |
| Philip Fisher | 75B | 39D | RMD |
| Peter Lynch | 58C | 28F | RMD |
| Joel Greenblatt | 47D | 48D | TMO |
| Charlie Munger | 69B | 51D | RMD |
| Terry Smith | 73B | 44D | RMD |
Side-by-side metrics
| Metric | RMD | TMO |
|---|---|---|
| Market cap | $30.31B | $166.32B |
| P/E (TTM) | 19.6x | 23.8x |
| EV/EBIT | 17.1x | 25.0x |
| ROIC (TTM) | 19.63% | 7.33% |
| Gross margin | 61.69% | 39.41% |
| Net margin | 27.44% | 15.18% |
| Revenue CAGR 5y | 12.64% | 3.25% |
| EPS CAGR 5y | 30.73% | -2.43% |
| Debt / Equity | 0.1x | 0.8x |
| Dividend yield | 1.14% | 0.4% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- EPS CAGR 5y30.73%vs -2.43%+108%
- Debt / Equity0.1xvs 0.8x+84%
- Revenue CAGR 5y12.64%vs 3.25%+74%
- Dividend yield1.14%vs 0.4%+65%
TMO leads on
- Market cap$166.32Bvs $30.31B+82%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.